MedWatch

Carnegie slashes Bavarian Nordic share target

The investment bank has also changed its recommendation for investors of the Danish biotech company to ”hold” their investments.

Photo: Sven Hoppe/AP/Ritzau Scanpix

Bavarian Nordic is no longer on Carnegie’s list of what to buy as the investment bank has lowered its recommendation from ”buy” to ”hold,” according to Bloomberg News.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs